AADI vs. EYEN, OCUP, GANX, HCWB, BLRX, IMRX, CLNN, CKPT, ANVS, and EGRX
Should you be buying Aadi Bioscience stock or one of its competitors? The main competitors of Aadi Bioscience include Eyenovia (EYEN), Ocuphire Pharma (OCUP), Gain Therapeutics (GANX), HCW Biologics (HCWB), BioLineRx (BLRX), Immuneering (IMRX), Clene (CLNN), Checkpoint Therapeutics (CKPT), Annovis Bio (ANVS), and Eagle Pharmaceuticals (EGRX). These companies are all part of the "pharmaceutical preparations" industry.
Aadi Bioscience (NASDAQ:AADI) and Eyenovia (NASDAQ:EYEN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, community ranking, media sentiment and earnings.
Aadi Bioscience has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, Eyenovia has a beta of 1.71, meaning that its stock price is 71% more volatile than the S&P 500.
Eyenovia has a net margin of 0.00% compared to Aadi Bioscience's net margin of -288.72%. Aadi Bioscience's return on equity of -61.83% beat Eyenovia's return on equity.
52.1% of Aadi Bioscience shares are owned by institutional investors. Comparatively, 25.8% of Eyenovia shares are owned by institutional investors. 35.8% of Aadi Bioscience shares are owned by insiders. Comparatively, 7.1% of Eyenovia shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Eyenovia has lower revenue, but higher earnings than Aadi Bioscience. Eyenovia is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.
Eyenovia received 158 more outperform votes than Aadi Bioscience when rated by MarketBeat users. Likewise, 65.00% of users gave Eyenovia an outperform vote while only 47.83% of users gave Aadi Bioscience an outperform vote.
Aadi Bioscience presently has a consensus target price of $20.50, indicating a potential upside of 1,020.22%. Eyenovia has a consensus target price of $10.00, indicating a potential upside of 843.40%. Given Aadi Bioscience's higher possible upside, equities research analysts plainly believe Aadi Bioscience is more favorable than Eyenovia.
In the previous week, Aadi Bioscience had 8 more articles in the media than Eyenovia. MarketBeat recorded 13 mentions for Aadi Bioscience and 5 mentions for Eyenovia. Eyenovia's average media sentiment score of 0.34 beat Aadi Bioscience's score of -0.02 indicating that Eyenovia is being referred to more favorably in the news media.
Summary
Eyenovia beats Aadi Bioscience on 9 of the 17 factors compared between the two stocks.
Get Aadi Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for AADI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AADI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aadi Bioscience Competitors List
Related Companies and Tools
